| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-05-19 | Intarcia Therapeutics (USA - CA) | nomination |
Metabolic diseases | Nomination | ||
| 2015-05-19 | Pharmaxis (Australia) | restructuring |
Restructuring | |||
| 2015-05-19 | Janssen Pharmaceuticals, a J&J company (USA - NJ) Achillion Pharmaceuticals (USA - CT) | hepatitis C virus (HCV) assets which include ACH-3102 (odalasvir), ACH-3422 and sovaprevir | hepatitis C | licensing development commercialisation |
Infectious diseases | Licensing agreement |
| 2015-05-19 | Genmab (Denmark) BioNTech (Germany) | bispecific antibody products using Genmab\'s DuoBody technology platform | R&D development commercialisation |
Cancer - Oncology | R&D agreement | |
| 2015-05-19 | Acucela (USA - MA) | nomination |
Ophtalmological diseases | Nomination | ||
| 2015-05-19 | Medicago (Canada) | construction of new premises |
Allergic diseases | Construction of new premises | ||
| 2015-05-19 | Poxel (France) | nomination |
Metabolic diseases | Nomination | ||
| 2015-05-19 | Jacobs Engineering Group (USA - CA) BMS (USA - NY) | biologics manufacturing facility in Cruiserath (Ireland) | construction of new premises services contract |
Technology - Services | Construction of new premises | |
| 2015-05-18 | AstraZeneca (UK) | construction of new premises |
Construction of new premises | |||
| 2015-05-18 | Ablynx (Belgium) Genzyme (USA - MA), a Sanofi company (France) | Nanobodies® against a target in multiple sclerosis | multiple sclerosis | R&D |
Autoimmune diseases - Neurodegenerative diseases | R&D agreement |
| 2015-05-18 | Pharming (The Netherlands) Clinigen (UK) | Ruconest® (conestat alfa) | hereditary angioedema (HAE) | collaboration |
Rare diseases - Genetic diseases - Hematological diseases | Collaboration agreement |
| 2015-05-18 | Chiasma (USA- MA - Israel) | nomination |
Nomination | |||
| 2015-05-16 | Complix (Belgium) | nomination |
Autoimmune diseases - Cancer - Oncology | Nomination | ||
| 2015-05-15 | Cortendo (Sweden) Aspireo Pharmaceuticals (Sweden) | somatoprim (DG3173 - somatostatin analogue) | acromegaly | product acquisition |
Rare diseases - Hormonal diseases - Endocrine diseases | Product acquisition |
| 2015-05-14 | Cortendo (Sweden) Antisense Therapeutics (Australia) | ATL1103 | acromegaly and other endocrine diseases | licensing |
Rare diseases - Hormonal diseases - Endocrine diseases | Licensing agreement |
| 2015-05-14 | Eli Lilly (USA - IN) Sanford-Burnham Medical Research Institute (USA - CA) | immunological therapies targeting multiple immune checkpoint modulators | lupus, Sjögren\'s Syndrome, inflammatory bowel disease and other autoimmune disorders | R&D |
Autoimmune diseases – Immunological diseases | R&D agreement |
| 2015-05-14 | Epirus Biopharmaceuticals (USA - MA) mAbxience (Switzerland) | BOW015 (biosimilar version of Remicade® (infliximab)) | rheumatoid arthritis | development, distribution | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Development agreement |
| 2015-05-14 | Pfizer (USA - NY) | Resignation | ||||
| 2015-05-14 | Aegerion Pharmaceuticals (USA - MA) | resignation |
Rare diseases - Genetic diseases - Metabolic diseases | Resignation | ||
| 2015-05-14 | Pieris (Germany) | nomination |
Nomination |
